Tirzepatide for Liver Health: What the Evidence Shows
What human and animal studies show about Tirzepatide for liver health, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 143
- PubMed records, our ledger
- Animal studies
- 15
- PubMed records, our ledger
- Studies we summarised
- 3
- with an outcome for liver health
Evidence for liver health
Each row is an outcome related to liver health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Resolution of MASH without worsening of fibrosis | MASH resolved without worsening fibrosis in 44% (5 mg), 56% (10 mg) and 62% (15 mg) vs 10% with placebo. | Human RCTn = 190 | The New England journal of medicine 2024, PMID 38856224 |
| Liver fat content | Absolute liver fat fell by 8·09% with pooled tirzepatide 10 and 15 mg versus 3·38% with insulin degludec at week 52. | Human RCTn = 296 | The lancet. Diabetes & endocrinology 2022, PMID 35468325 |
| Visceral and abdominal fat | Tirzepatide significantly reduced liver fat content and visceral and abdominal subcutaneous adipose tissue volumes versus insulin degludec. | Human RCTn = 296 | The lancet. Diabetes & endocrinology 2022, PMID 35468325 |
| NASH biomarkers | Higher tirzepatide doses significantly decreased NASH-related biomarkers and increased adiponectin (post hoc analysis). | Human RCT | Diabetes care 2020, PMID 32291277 |
PubMed records for Tirzepatide and liver health: 143 human, 15 animal (search counts, not studies we reviewed). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Fatty liver, MASH and tirzepatide
MedlinePlus says steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver.[4]
In the SYNERGY-NASH phase 2 trial of people with MASH and moderate or severe fibrosis, MASH resolved without worsening fibrosis in 10% on placebo against 44%, 56% and 62% at 5, 10 and 15 mg.[1]
Fibrosis improved by at least one stage in 30% on placebo and in 55%, 51% and 51% on tirzepatide, a smaller gap than the MASH-resolution result.[1]
Liver fat and enzymes in diabetes trials
In an MRI substudy of people with type 2 diabetes, liver fat fell significantly more with tirzepatide 10 mg or 15 mg than with insulin degludec.[2]
A post hoc biomarker analysis found ALT fell at all doses and higher doses reduced fibrosis markers K-18 and Pro-C3 compared with placebo.[3]
Label position
The Zepbound label's indications are weight reduction and obstructive sleep apnea, with no MASH indication.[5]
Other peptides people research for liver health
All peptides for liver health, comparedCommon questions
Does Tirzepatide help with liver health?
The strongest study we summarise for liver health is human rct evidence, across 3 studies with an outcome for liver health. A trial result is not an approval; see the legal status.
Is Tirzepatide approved for liver health?
Tirzepatide is FDA approved (Mounjaro, Zepbound). Which conditions that approval covers is set by the label; use for anything else is off-label.
What is the best peptide for liver health?
There is no single answer. Our liver health overview compares each candidate by evidence grade and legal status rather than by popularity.
Is tirzepatide approved for fatty liver?
No: neither label lists MASH or fatty liver as an indication; the evidence is from phase 2 trials and substudies.[5]
Does tirzepatide reduce liver fat?
In the SURPASS-3 MRI substudy the 10 and 15 mg groups lost more liver fat than insulin degludec.[2]
Can tirzepatide reverse MASH?
In the phase 2 trial, MASH resolved without worse fibrosis in up to 62% on tirzepatide against 10% on placebo.[1]
More on Tirzepatide
Sources
- 1Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.The New England journal of medicine · 2024PMID 38856224Accessed 2 Oct 2026
- 2Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.The lancet. Diabetes & endocrinology · 2022PMID 35468325Accessed 2 Oct 2026
- 3Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.Diabetes care · 2020PMID 32291277Accessed 2 Oct 2026
- 4medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
- 5ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.